Ketoprofen
Company: Schein Pharmaceutical
Approval Status: Approved December 1997
Treatment for: anti-inflammatory
Areas: Musculoskeletal; Rheumatology
General Information
Other Useful Resources
Ketoprofen, the generic equivalent of Wyeth Ayerst's Oruvail, has received approval as a non-steroidal anti-inflammatory. Ketoprofen will be available in 200 mg extended release capsules.
The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
